Sonnet BioTherapeutics Holdings, Inc. has sold $4.8 million of its New Jersey net operating losses and expects to receive $4.3 million in net proceeds. The company is also addressing its non-compliance with the minimum stockholders equity requirement for continued listing on Nasdaq.